ArticleItalian journal of pediatrics2026
COVID-19 infection is associated with anti-M alloantibody development in pediatric patients: immunological characteristics and clinical implications for transfusion safety.
Article in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-M antibodies are commonly observed as naturally occurring antibodies in the MNS blood group system, and their production has been linked to various microbial infections through molecular mimicry. However, the association between COVID-19 infection and anti-M antibody development in pediatric patients remains unexplored.
methodsThis retrospective matched case-control study included 31 anti-M positive pediatric patients and 31 matched anti-M negative controls with NN phenotype from October 2022 to May 2025. Anti-M isotypes (IgM/IgG) were distinguished using saline and dithiothreitol-preserved plasma methods, followed by titer determination and IgG subclass analysis. Plasma cytokines were quantified by flow cytometry. COVID-19 infection history within 2 years was recorded.
resultsAnti-M positive patients had significantly higher COVID-19 infection rates than controls (54.84% vs. 19.35%, OR = 5.06, P = 0.008); this association remained significant after adjustment for age and sex (adjusted OR = 5.35, 95% CI: 1.67–17.17, P = 0.005). Among those with IgG antibodies, anti-M IgG titers inversely correlated with the interval since COVID-19 infection (r = -0.63, P = 0.008). Reactive IgG (IgG1/IgG3) exhibited significantly higher titers than inactive IgG (median 64 vs. 4, P < 0.001), with all high-titer cases (≥ 64) exclusively in the reactive group (11/31, 35.48%). Anti-M positive patients showed elevated IL-8 (P = 0.006) and IL-12p70 (P = 0.029), and unexpectedly lower bilirubin levels (P < 0.01), suggesting metabolic adaptation rather than hemolysis.
conclusionCOVID-19 infection is significantly associated with anti-M alloantibody development in NN-phenotype children, with over one-third reaching clinically significant titers. These findings suggest that enhanced antibody screening should be considered for pediatric transfusion candidates with recent viral infections, although the single-center design with modest sample size (31 pairs) warrants multi-center validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.